The Lions Eye Institute (LEI) is strengthening its ties with Indonesian researchers following the successful launch of a new glaucoma drainage device produced for only one-tenth of the cost of competing products. Read more
Internationally recognised optometrist joins George & Matilda
Gerry & Johnson Optometrists, owned and operated by renowned Australian clinical optometrist and researcher Dr Kate Gifford, is the latest high-profile practice to join George & Matilda Eyecare (GME). Read more
IOLs: Bringing the presbyope into focus
As intraocular lenses continue to improve, their popularity is increasing among a variety of patients – even those who don’t require cataract surgery. MYLES HUME asks what it takes to treat one particular type of patient: the presbyope. Read more
Artificial Intelligence: Will it replace ophthalmologists?
Ophthalmology’s lead role in the medical use of artificial intelligence (AI) and its future role in the profession were among the key talking points at the recently concluded RANZCO Scientific Congress. Read more
Zeiss gifts ‘gold standard’ optical biometry device to Indigenous eye clinic
Carl Zeiss Meditec has donated its latest generation optical biometry device to the Indigenous Diabetes Eyes and Screening (IDEAS) Van. Read more
Artificial intelligence used to diagnose uveitis
Artificial intelligence is being used to extract hidden information from retinal images of patients with birdshot uveitis, in a hope it could lead to more timely diagnosis for the rare condition. Read more
Afghan refugee and optometrist recognised in Deakin Alumni awards
A Deakin optometry graduate, who fled his war-torn homeland for Australia and has gone on to change lives through philanthropy, has been recognised with a top university award. Read more
New Specsavers report shows impact of eye health strategies
Specsavers’ latest snapshot into Australian eye health has revealed referrals for eye disease are soaring to unprecedented levels thanks to the systematic use of imaging technology and ophthalmology-led education, as well as other clinical interventions. Read more
Biogen unveils plan to commercialise Eylea and Lucentis generics
Multinational biotech company Biogen has proposed a deal worth up to US$310 million (AU$453 m) to supply biosimilar treatments of Lucentis and Eylea to major global markets, including Australia. Read more
Traces of anti-VEGF drugs found in breast milk
Anti-vascular endothelial growth factor (anti-VEGF) drugs have been identified in breast milk, prompting warnings from the researchers that the use of these medications during breastfeeding could affect developing infants. Read more